Dr. Reddy's rituximab biosimilar wins FDA approval for US market

Reuters2026/08/03 10:03

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Dr. Reddy’s won U.S. FDA clearance for a rituximab biosimilar, a copy of Roche’s Rituxan, expanding its U.S. biosimilars portfolio.
Fresenius Kabi secured exclusive U.S. commercialization rights under a prior agreement.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dr. Reddy's Laboratories Limited published the original content used to generate this news brief on August 01, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Dr. Reddy's rituximab biosimilar wins FDA approval for US market

You may also like

Crypto prices